Traditional corticosteroid and antiinflammatory therapy should be supplemented with new immunocorrective drugs in patients with traumatic uveitis and ocular subatrophy. Immunotherapy is a pathogenetically justified and perspective trend in multiple-modality treatment of patients with injuries to the organ of vision. The authors validate the use of immunocorrectors utilized in general transplantology for preventing rejection crisis. Immunostimulants or immunosuppresants can be added to treatment protocols for patients with traumatic uveitis, depending on the changes in the patient's immune status. New immunotropic drugs affecting all components of immunity are needed.